与术前化疗的病理反应相比,结直肠癌肝转移之间免疫特征的同质性更好地识别预后良好的患者。

IF 7.2 2区 医学
Oncoimmunology Pub Date : 2023-09-14 eCollection Date: 2023-01-01 DOI:10.1080/2162402X.2023.2253642
David Henault, David Stephen, Pierre-Antoine St-Hilaire, Nouredin Messaoudi, Franck Vandenbroucke-Menu, Eve Simoneau, Zhixia Rong, Marylène Plasse, Richard Létourneau, André Roy, Michel Dagenais, Réal Lapointe, Bich Nguyen, Anne-Marie Mes-Masson, G Soucy, Simon Turcotte
{"title":"与术前化疗的病理反应相比,结直肠癌肝转移之间免疫特征的同质性更好地识别预后良好的患者。","authors":"David Henault,&nbsp;David Stephen,&nbsp;Pierre-Antoine St-Hilaire,&nbsp;Nouredin Messaoudi,&nbsp;Franck Vandenbroucke-Menu,&nbsp;Eve Simoneau,&nbsp;Zhixia Rong,&nbsp;Marylène Plasse,&nbsp;Richard Létourneau,&nbsp;André Roy,&nbsp;Michel Dagenais,&nbsp;Réal Lapointe,&nbsp;Bich Nguyen,&nbsp;Anne-Marie Mes-Masson,&nbsp;G Soucy,&nbsp;Simon Turcotte","doi":"10.1080/2162402X.2023.2253642","DOIUrl":null,"url":null,"abstract":"<p><p>In colorectal cancer liver metastases (CRLM), the density of tumor-infiltrating lymphocytes, the expression of class I major histocompatibility complex (MHC-I), and the pathological response to preoperative chemotherapy have been associated with oncological outcomes after complete resection. However, the prognostic significance of the heterogeneity of these features in patients with multiple CRLMs remains under investigation. We used a tissue microarray of 220 mismatch repair-gene proficient CRLMs resected in 97 patients followed prospectively to quantify CD3<sup>+</sup> T cells and MHC-I by immunohistochemistry. Histopathological response to preoperative chemotherapy was assessed using standard scoring systems. We tested associations between clinical, immunological, and pathological features with oncologic outcomes. Overall, 29 patients (30.2%) had CRLMs homogeneous for CD3+ T cell infiltration and MHC-I. Patients with immune homogeneous compared to heterogeneous CRLMs had longer median time to recurrence (TTR) (30 vs. 12 months, <i>p</i> = .0018) and disease-specific survival (DSS) (not reached vs. 48 months, <i>p</i> = .0009). At 6 years, 80% of the patients with immune homogeneous CRLMs were still alive. Homogeneity of response to preoperative chemotherapy was seen in 60 (61.9%) and 69 (80.2%) patients according to different grading systems and was not associated with TTR or DSS. CD3 and MHC-I heterogeneity was independent of response to pre-operative chemotherapy and of other clinicopathological variables for their association with oncological outcomes. In patients with multiple CRLMs resected with curative intent, similar adaptive immune features seen across metastases could be more informative than pathological response to pre-operative chemotherapy in predicting oncological outcomes.</p>","PeriodicalId":19683,"journal":{"name":"Oncoimmunology","volume":"12 1","pages":"2253642"},"PeriodicalIF":7.2000,"publicationDate":"2023-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503458/pdf/","citationCount":"0","resultStr":"{\"title\":\"Homogeneity in immune features between colorectal liver metastases better identifies patients with good prognosis compared to pathological response to preoperative chemotherapy.\",\"authors\":\"David Henault,&nbsp;David Stephen,&nbsp;Pierre-Antoine St-Hilaire,&nbsp;Nouredin Messaoudi,&nbsp;Franck Vandenbroucke-Menu,&nbsp;Eve Simoneau,&nbsp;Zhixia Rong,&nbsp;Marylène Plasse,&nbsp;Richard Létourneau,&nbsp;André Roy,&nbsp;Michel Dagenais,&nbsp;Réal Lapointe,&nbsp;Bich Nguyen,&nbsp;Anne-Marie Mes-Masson,&nbsp;G Soucy,&nbsp;Simon Turcotte\",\"doi\":\"10.1080/2162402X.2023.2253642\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In colorectal cancer liver metastases (CRLM), the density of tumor-infiltrating lymphocytes, the expression of class I major histocompatibility complex (MHC-I), and the pathological response to preoperative chemotherapy have been associated with oncological outcomes after complete resection. However, the prognostic significance of the heterogeneity of these features in patients with multiple CRLMs remains under investigation. We used a tissue microarray of 220 mismatch repair-gene proficient CRLMs resected in 97 patients followed prospectively to quantify CD3<sup>+</sup> T cells and MHC-I by immunohistochemistry. Histopathological response to preoperative chemotherapy was assessed using standard scoring systems. We tested associations between clinical, immunological, and pathological features with oncologic outcomes. Overall, 29 patients (30.2%) had CRLMs homogeneous for CD3+ T cell infiltration and MHC-I. Patients with immune homogeneous compared to heterogeneous CRLMs had longer median time to recurrence (TTR) (30 vs. 12 months, <i>p</i> = .0018) and disease-specific survival (DSS) (not reached vs. 48 months, <i>p</i> = .0009). At 6 years, 80% of the patients with immune homogeneous CRLMs were still alive. Homogeneity of response to preoperative chemotherapy was seen in 60 (61.9%) and 69 (80.2%) patients according to different grading systems and was not associated with TTR or DSS. CD3 and MHC-I heterogeneity was independent of response to pre-operative chemotherapy and of other clinicopathological variables for their association with oncological outcomes. In patients with multiple CRLMs resected with curative intent, similar adaptive immune features seen across metastases could be more informative than pathological response to pre-operative chemotherapy in predicting oncological outcomes.</p>\",\"PeriodicalId\":19683,\"journal\":{\"name\":\"Oncoimmunology\",\"volume\":\"12 1\",\"pages\":\"2253642\"},\"PeriodicalIF\":7.2000,\"publicationDate\":\"2023-09-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503458/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncoimmunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/2162402X.2023.2253642\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncoimmunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/2162402X.2023.2253642","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

在结直肠癌癌症肝转移(CRLM)中,肿瘤浸润性淋巴细胞的密度、I类主要组织相容性复合物(MHC-I)的表达以及术前化疗的病理反应与完全切除后的肿瘤结果相关。然而,这些特征的异质性在多发CRLMs患者中的预后意义仍在研究中。我们使用了一个组织微阵列,对97名患者中切除的220个错配修复基因丰富的CRLMs进行了前瞻性研究,并通过免疫组织化学对CD3+T细胞和MHC-I进行了定量。使用标准评分系统评估术前化疗的组织病理学反应。我们测试了临床、免疫学和病理学特征与肿瘤学结果之间的关系。总的来说,29名患者(30.2%)的CRLMs在CD3+T细胞浸润和MHC-I方面是同质的。与异质性CRLMs相比,免疫同种型CRLMs患者的中位复发时间(TTR)更长(30 vs.12 月,p = .0018)和疾病特异性生存率(DSS)(未达到vs.48 月,p = .0009)。在6 年,80%的免疫同质CRLMs患者仍然活着。根据不同的分级系统,60名(61.9%)和69名(80.2%)患者对术前化疗的反应是一致的,与TTR或DSS无关。CD3和MHC-I的异质性与术前化疗的反应以及与肿瘤学结果相关的其他临床病理变量无关。在有治疗意图切除多个CRLMs的患者中,在预测肿瘤学结果方面,在转移瘤中观察到的类似适应性免疫特征可能比术前化疗的病理反应更具信息性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Homogeneity in immune features between colorectal liver metastases better identifies patients with good prognosis compared to pathological response to preoperative chemotherapy.

Homogeneity in immune features between colorectal liver metastases better identifies patients with good prognosis compared to pathological response to preoperative chemotherapy.

Homogeneity in immune features between colorectal liver metastases better identifies patients with good prognosis compared to pathological response to preoperative chemotherapy.

Homogeneity in immune features between colorectal liver metastases better identifies patients with good prognosis compared to pathological response to preoperative chemotherapy.

In colorectal cancer liver metastases (CRLM), the density of tumor-infiltrating lymphocytes, the expression of class I major histocompatibility complex (MHC-I), and the pathological response to preoperative chemotherapy have been associated with oncological outcomes after complete resection. However, the prognostic significance of the heterogeneity of these features in patients with multiple CRLMs remains under investigation. We used a tissue microarray of 220 mismatch repair-gene proficient CRLMs resected in 97 patients followed prospectively to quantify CD3+ T cells and MHC-I by immunohistochemistry. Histopathological response to preoperative chemotherapy was assessed using standard scoring systems. We tested associations between clinical, immunological, and pathological features with oncologic outcomes. Overall, 29 patients (30.2%) had CRLMs homogeneous for CD3+ T cell infiltration and MHC-I. Patients with immune homogeneous compared to heterogeneous CRLMs had longer median time to recurrence (TTR) (30 vs. 12 months, p = .0018) and disease-specific survival (DSS) (not reached vs. 48 months, p = .0009). At 6 years, 80% of the patients with immune homogeneous CRLMs were still alive. Homogeneity of response to preoperative chemotherapy was seen in 60 (61.9%) and 69 (80.2%) patients according to different grading systems and was not associated with TTR or DSS. CD3 and MHC-I heterogeneity was independent of response to pre-operative chemotherapy and of other clinicopathological variables for their association with oncological outcomes. In patients with multiple CRLMs resected with curative intent, similar adaptive immune features seen across metastases could be more informative than pathological response to pre-operative chemotherapy in predicting oncological outcomes.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Oncoimmunology
Oncoimmunology ONCOLOGY-IMMUNOLOGY
CiteScore
12.80
自引率
2.80%
发文量
276
期刊介绍: Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy. While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信